Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

CaboLife: A Prospective Non-Interventional Study on Effectiveness and Safety of Cabozantinib in Real-Life Setting for Previously Treated Patients With Neuroendocrine Tumour

NCT07314164 is registered in ClinicalTrials.gov with Ipsen as lead sponsor.

NCT NCT07314164
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07314164 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
CaboLife: A Prospective Non-Interventional Study on Effectiveness and Safety of Cabozantinib in Real-Life Setting for Previously Treated Patients With Neuroendocrine Tumour
Lead sponsor
Ipsen
Phase
Observational
Overall status
Recruiting
Start date
December 17, 2025
Completion date
December 31, 2028
Enrollment
150 (estimated)
Sites
41

Conditions

As the registry lists them; a condition with its own page is linked.

neuroendocrine tumors